Reviewing Turnstone Biologics (NASDAQ:TSBX) and Mesoblast (NASDAQ:MESO)

Turnstone Biologics (NASDAQ:TSBXGet Free Report) and Mesoblast (NASDAQ:MESOGet Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership.


This table compares Turnstone Biologics and Mesoblast’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Turnstone Biologics N/A N/A -55.83%
Mesoblast -1,061.43% -16.32% -12.26%

Insider and Institutional Ownership

46.4% of Turnstone Biologics shares are held by institutional investors. Comparatively, 2.6% of Mesoblast shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Turnstone Biologics and Mesoblast’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Turnstone Biologics $29.75 million 2.32 -$30.83 million N/A N/A
Mesoblast $7.50 million 29.24 -$81.89 million ($1.12) -1.93

Turnstone Biologics has higher revenue and earnings than Mesoblast.

Analyst Recommendations

This is a summary of current recommendations for Turnstone Biologics and Mesoblast, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Turnstone Biologics 0 2 2 0 2.50
Mesoblast 1 3 2 0 2.17

Turnstone Biologics currently has a consensus price target of $19.00, indicating a potential upside of 535.45%. Mesoblast has a consensus price target of $13.67, indicating a potential upside of 532.72%. Given Turnstone Biologics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Turnstone Biologics is more favorable than Mesoblast.


Turnstone Biologics beats Mesoblast on 7 of the 10 factors compared between the two stocks.

About Turnstone Biologics

(Get Free Report)

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

About Mesoblast

(Get Free Report)

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and GrĂ¼nenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Receive News & Ratings for Turnstone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turnstone Biologics and related companies with's FREE daily email newsletter.